How to Get Dayvigo (Lemborexant) in California

What Dayvigo Is and Why California Prescribing Rules Matter

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for treating insomnia characterized by difficulty with sleep onset and sleep maintenance in adults [1]. Unlike older sedative-hypnotics such as zolpidem, lemborexant works by blocking wake-promoting orexin neuropeptides rather than broadly suppressing CNS activity.

Mechanism and Clinical Distinction

The orexin system drives wakefulness. By selectively antagonizing OX1R and OX2R receptors, lemborexant reduces the arousal signal without the widespread GABA-ergic depression associated with benzodiazepine receptor agonists [2]. This pharmacologic distinction matters clinically: the SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg significantly improved latency to persistent sleep (LPS) and wake after sleep onset (WASO) versus placebo at one month, with sustained efficacy through six months [3].

California's Regulatory Framework

California classifies Dayvigo under federal Schedule IV rules, meaning any prescriber with a valid DEA registration and California state license can prescribe it. The state's telehealth parity laws (California Business and Professions Code Section 2290.5) permit initial prescribing of Schedule IV drugs via audiovisual telehealth encounters without a prior in-person visit [4]. This opens a practical pathway for patients who lack proximity to a sleep specialist.

Step-by-Step Prescription Process in California

Getting Dayvigo in California follows a predictable sequence. Most patients move from consultation to pharmacy pickup within one week.

Step 1: Schedule a Clinical Evaluation

Book an appointment with a licensed prescriber. This can be a primary care physician, a sleep medicine specialist, a nurse practitioner, or a physician assistant. California law permits all of these provider types to prescribe Schedule IV medications, though NPs and PAs must operate within their scope of practice and any applicable collaborative agreements [4].

Step 2: Complete the Insomnia Assessment

Your clinician will assess sleep-onset latency, nighttime awakenings, daytime impairment, and duration of symptoms. Expect questions about prior treatments, alcohol use, and concurrent medications. The American Academy of Sleep Medicine (AASM) recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with pharmacotherapy appropriate when CBT-I is unavailable, insufficient, or not preferred by the patient [5].

Step 3: Obtain the Prescription

If lemborexant is appropriate, your provider will e-prescribe Dayvigo to a California pharmacy. Starting dose is 5 mg taken once nightly, no more than 30 minutes before bedtime, with at least 7 hours of planned sleep remaining. The dose may be increased to 10 mg based on clinical response [1].

Step 4: Fill at a Licensed Pharmacy

Any California-licensed retail or mail-order pharmacy can dispense Dayvigo. If your pharmacy does not stock it, request a direct order from the wholesaler. Specialty pharmacies and 503A compounding pharmacies licensed by the California Board of Pharmacy can also fill prescriptions for lemborexant when clinically indicated [6].

Telehealth Pathways for California Residents

Telehealth is one of the most efficient routes to a Dayvigo prescription in California. The state has some of the broadest telehealth statutes in the country.

How California Telehealth Law Applies to Dayvigo

Under Business and Professions Code Section 2290.5, California does not require a prior in-person visit before a telehealth prescriber can issue a prescription for a Schedule IV substance [4]. The prescriber must verify the patient's identity, perform an adequate clinical evaluation via synchronous audio-video, and document the encounter in the medical record. Telephone-only encounters are insufficient for initial controlled substance prescriptions.

What to Expect From a Telehealth Visit

A typical Dayvigo telehealth consultation in California lasts 15 to 30 minutes. Your provider will review your sleep history, screen for obstructive sleep apnea (OSA) using tools like the STOP-BANG questionnaire, and discuss medication options. If OSA is suspected, a home sleep test may be ordered before initiating Dayvigo. The prescription is sent electronically to your chosen California pharmacy.

Selecting a Telehealth Provider

When choosing a telehealth platform, verify that the prescriber holds an active California medical license (searchable at the Medical Board of California's license lookup), carries a valid DEA registration, and offers synchronous video visits rather than asynchronous questionnaire-only models. HealthRX.com connects California patients with board-certified providers experienced in sleep medicine pharmacotherapy.

Insurance Coverage and Prior Authorization in California

Most California insurance plans cover Dayvigo, but nearly all require some form of utilization management. Understanding the prior authorization process can shave days off your wait time.

Medi-Cal (California Medicaid)

Medi-Cal covers lemborexant with prior authorization [7]. The Department of Health Care Services (DHCS) typically requires documentation that the patient has tried and failed, or has a contraindication to, at least one generic sleep agent (such as zolpidem, eszopiclone, or suvorexant) before approving Dayvigo. Your prescriber submits the PA request, and Medi-Cal must respond within 24 hours for urgent requests or 5 business days for standard requests.

Commercial Insurance Plans

Most commercial plans in California (including those offered through Covered California) place Dayvigo on Tier 3 or specialty tiers. Common PA criteria include:

• Diagnosis of insomnia disorder (ICD-10 G47.00 or G47.09)
• Documentation of inadequate response to or intolerance of one or two formulary alternatives
• Confirmation that the patient does not have severe hepatic impairment (Child-Pugh C), which contraindicates lemborexant use [1]
• Prescriber attestation that the patient has been counseled on sleep hygiene and, where available, CBT-I

Documents Your Prescriber Should Prepare

Prior authorization goes faster when the submission includes chart notes with sleep-onset latency and WASO data, a list of previously tried medications with dates and reasons for discontinuation, and any relevant sleep study results. A well-prepared PA packet can reduce turnaround from 5 days to 48 hours.

Cost Without Insurance

Without insurance, Dayvigo's average retail price in California runs approximately $400 to $450 for a 30-day supply. Eisai offers a manufacturer savings card that may reduce copays for commercially insured patients. GoodRx and similar discount programs may bring the cash price to approximately $350 at select pharmacies [8].

Labs and Clinical Monitoring Before Starting Dayvigo

Dayvigo does not require extensive baseline laboratory work, but targeted assessments ensure safe prescribing.

Recommended Pre-Prescription Workup

The FDA label recommends evaluating for narcolepsy, cataplexy, and sleep apnea before prescribing any DORA [1]. In practical terms, your California prescriber should:

• Screen for OSA with the STOP-BANG or Epworth Sleepiness Scale
• Review hepatic function if liver disease is suspected (lemborexant is metabolized primarily by CYP3A4, and moderate hepatic impairment requires dose reduction to 5 mg) [1]
• Assess for concurrent use of moderate or strong CYP3A4 inhibitors, which are contraindicated or require dose adjustment
• Screen for depression and suicidal ideation, as insomnia is a common comorbid symptom

Ongoing Monitoring

No routine lab draws are mandated during Dayvigo therapy. Clinical follow-up at 2 to 4 weeks after initiation is standard practice to assess efficacy, side effects (most commonly somnolence, headache, and dizziness), and the need for dose adjustment [3].

503A Compounding Pharmacies in California

California has a strong compounding pharmacy infrastructure regulated by the California State Board of Pharmacy.

When Compounding Applies

Most patients will fill brand-name Dayvigo at a retail pharmacy. Compounding becomes relevant when a patient needs an alternative dosage form (such as a liquid suspension for swallowing difficulty) or when supply disruptions affect commercial availability. 503A pharmacies in California can compound lemborexant pursuant to a valid patient-specific prescription [6].

Licensing and Oversight

California 503A pharmacies must hold a current Board of Pharmacy license and comply with California Business and Professions Code Sections 4126 and 4127. They may ship compounded medications to patients within California. Out-of-state 503B outsourcing facilities registered with the FDA can also ship to California patients, though these typically serve institutional rather than individual-patient orders.

Who Can Prescribe Dayvigo in California

California's prescriber field for Schedule IV medications is broader than many states. This works in patients' favor when seeking timely access.

Physicians (MD and DO)

Any California-licensed physician with a DEA registration can prescribe Dayvigo. Sleep medicine board certification is not required, though referral to a sleep specialist is appropriate for complex cases involving comorbid OSA, circadian rhythm disorders, or treatment-resistant insomnia.

Nurse Practitioners

California Assembly Bill 890 (effective January 2023) grants nurse practitioners with a Doctor of Nursing Practice or equivalent training the ability to practice independently, including prescribing Schedule II through V controlled substances, without a standardized procedure agreement after completing a 4,600-hour transition-to-practice period [9]. NPs who have not completed this transition must maintain a collaborative agreement with a physician.

Physician Assistants

PAs in California prescribe under a practice agreement with a supervising physician. Schedule IV prescribing authority is standard within PA scope of practice. A PA can evaluate, diagnose, and prescribe Dayvigo during a telehealth or in-person visit.

Transferring a Dayvigo Prescription to California

Patients relocating to California or visiting from another state can transfer an existing Dayvigo prescription.

How Transfer Works

Under California Board of Pharmacy regulations, a pharmacist in California can receive a transferred prescription for a Schedule IV drug from an out-of-state pharmacy, provided the transfer occurs between two pharmacies that share a real-time online database, or by direct pharmacist-to-pharmacist communication [6]. Schedule IV prescriptions may be transferred once during the valid prescription period.

Practical Steps

Contact your current pharmacy and request a transfer to a California pharmacy of your choice. Provide the receiving pharmacy's name, address, and phone number. The transfer typically completes within 24 to 48 hours. Alternatively, your new California provider can write a fresh prescription based on your medical records.

Timeline: From Visit to First Dose

The total time from initial consultation to taking your first Dayvigo tablet varies by insurance status and prescriber availability.

• No PA required (cash pay or pre-approved formulary): 1 to 3 days. Schedule a telehealth visit, receive the e-prescription, fill at a local pharmacy.
• Commercial insurance with PA: 3 to 7 business days. Your prescriber submits the PA, the insurer reviews, and the pharmacy fills upon approval.
• Medi-Cal with PA: 3 to 10 business days. DHCS standard review is 5 business days; urgent requests are processed within 24 hours.

Delays most commonly occur when the PA submission lacks documentation of prior medication trials. Confirm with your provider that chart notes are attached before submission.

Clinical Efficacy Data Supporting Lemborexant

Prescribers and patients benefit from understanding the trial data behind Dayvigo's approval and its place in the DORA class.

SUNRISE-1 Trial

The key SUNRISE-1 trial enrolled 1,006 adults aged 55 and older with insomnia and randomized them to lemborexant 5 mg, 10 mg, or placebo [3]. At the primary endpoint of one month, lemborexant 5 mg reduced LPS by 10.7 minutes and WASO by 20.1 minutes versus placebo (P<0.001 for both). Lemborexant 10 mg reduced LPS by 12.6 minutes and WASO by 28.2 minutes versus placebo. Efficacy was maintained through the 6-month treatment period. Next-morning residual sleepiness, measured by the Karolinska Sleepiness Scale, did not differ significantly from placebo at either dose.

SUNRISE-2 Trial

The SUNRISE-2 trial (N=949) studied adults aged 18 and older over 12 months and confirmed long-term safety and sustained efficacy without evidence of rebound insomnia upon discontinuation [10]. Incidence of falls, a concern with older sedative-hypnotics, was low across treatment arms.

Safety Profile

The most common adverse events in clinical trials were somnolence (reported in 7% of the 5 mg group and 10% of the 10 mg group vs. 1% placebo), headache, and abnormal dreams [1]. Sleep paralysis and hypnagogic hallucinations occurred in fewer than 1% of patients. Dayvigo carries no boxed warning.